We are live on
!
Find out more
Rockefeller Capital Management Portfolio holdings
AUM
$56.4B
1-Year Est. Return
24.96%
This Fund
S&P 500
This Quarter
Est. Return
+16.85%
1 Year Est. Return
+24.96%
3 Year Est. Return
+83.53%
5 Year Est. Return
+100.91%
10 Year Est. Return
–
AUM
$13.2B
AUM Growth
+$2.53B
(+24%)
Cap. Flow
+$1B
Cap. Flow
% of AUM
7.59%
Top 10 Holdings %
Top 10 Hldgs %
23.93%
Holding
3,118
New
401
Increased
1,400
Reduced
617
Closed
168
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$120M |
| 2 |
Globe Life
GL
|
+$115M |
| 3 |
MPT
Medical Properties Trust
MPT
|
+$91.5M |
| 4 |
Arch Capital
ACGL
|
+$69.2M |
| 5 |
Amazon
AMZN
|
+$45.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Progressive
PGR
|
+$138M |
| 2 |
GSK
GSK
|
+$98.7M |
| 3 |
Crown Holdings
CCK
|
+$92.3M |
| 4 |
American Water Works
AWK
|
+$54M |
| 5 |
SolarEdge
SEDG
|
+$45.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.64% |
| 2 | Financials | 15.05% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 9.61% |
| 5 | Communication Services | 7.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Pfizer
PFE
$147B
| $32.9M | 0.25% |
894,511
+110,675
| +14% | +$4.06M |
|
102
Simpson Manufacturing
SSD
$8.02B
| $32.6M | 0.25% |
348,756
-3,476
| -1% | -$323K |
|
|
ABMD
103
DELISTED
Abiomed Inc
ABMD
| $32.4M | 0.25% |
99,797
-2,939
| -3% | -$813K |
|
104
Walmart Inc
WMT
$891B
| $32.3M | 0.24% |
673,008
+75,732
| +13% | +$3.68M |
|
105
iShares Russell 2000 ETF
IWM
$82.6B
| $32.2M | 0.24% |
164,227
+17,591
| +12% | +$3.08M |
|
106
SPDR Gold Trust
GLD
$138B
| $31.4M | 0.24% |
175,790
+10,843
| +7% | +$1.91M |
|
107
Ionis Pharmaceuticals
IONS
$9.11B
| $31.3M | 0.24% |
554,172
-162,953
| -23% | -$8.12M |
|
|
DOCU
108
DocuSign
DOCU
$10.8B
| $30.6M | 0.23% |
137,872
-18,098
| -12% | -$4.07M |
|
109
Broadcom
AVGO
$2.02T
| $30.1M | 0.23% |
688,090
+66,440
| +11% | +$2.59M |
|
110
Texas Instruments
TXN
$257B
| $29.6M | 0.22% |
180,156
+33,720
| +23% | +$5.24M |
|
111
Accenture
ACN
$103B
| $29.3M | 0.22% |
112,273
+7,130
| +7% | +$1.71M |
|
112
Vanguard FTSE Emerging Markets ETF
VWO
$123B
| $29.2M | 0.22% |
583,271
-56,551
| -9% | -$2.66M |
|
113
AbbVie
ABBV
$429B
| $28.9M | 0.22% |
269,756
+40,665
| +18% | +$3.91M |
|
114
ExxonMobil
XOM
$633B
| $28.7M | 0.22% |
697,423
-29,217
| -4% | -$1.1M |
|
115
Edwards Lifesciences
EW
$51.2B
| $28.4M | 0.21% |
310,766
-24,359
| -7% | -$2.02M |
|
116
Intuitive Surgical
ISRG
$132B
| $28.2M | 0.21% |
103,299
+20,940
| +25% | +$5.2M |
|
117
Vanguard Morningstar Small-Cap Value ETF
VBR
$37.9B
| $27.9M | 0.21% |
196,158
+25,499
| +15% | +$3.29M |
|
118
Lockheed Martin
LMT
$134B
| $27.8M | 0.21% |
78,194
+29,264
| +60% | +$10.8M |
|
119
Blackrock
BLK
$174B
| $27.7M | 0.21% |
38,404
+2,903
| +8% | +$1.93M |
|
120
Cardlytics
CDLX
$24.3M
| $27M | 0.2% |
18,920
-68
| -0.4% | -$72.5K |
|
|
EVBG
121
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $26.9M | 0.2% |
180,395
+8,996
| +5% | +$1.15M |
|
122
Prologis
PLD
$131B
| $26.9M | 0.2% |
269,539
+30,577
| +13% | +$3.09M |
|
123
NextEra Energy
NEE
$178B
| $26.6M | 0.2% |
344,283
+137,391
| +66% | +$10.3M |
|
124
Idexx Laboratories
IDXX
$46B
| $26.2M | 0.2% |
52,322
+20
| +0% | +$8.95K |
|
125
iShares Russell 1000 Growth ETF
IWF
$127B
| $26M | 0.2% |
431,760
+30,712
| +8% | +$1.75M |
|
Similar funds
NAMI
Rockefeller Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Rockefeller Capital Management held 3,118 positions worth $13.2B, up 24% from $10.7B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Rockefeller Capital Management deployed $1B of net new capital in Q4 2020, opening 401 new positions and adding to 1,400 existing holdings. Its largest new stake was BridgeBio Pharma: 777,031 shares worth $55.3M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 21% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Progressive, an estimated $138M trimmed.
- Rockefeller Capital Management's largest Q4 2020 buy was BridgeBio Pharma: 777,031 shares worth $55.3M.
- Rockefeller Capital Management added most to Alibaba in Q4 2020, an estimated $120M increase.
- Rockefeller Capital Management's biggest Q4 2020 reduction was Progressive, cutting an estimated $138M.
- Rockefeller Capital Management fully exited Unilever NV New York Registry Shares in Q4 2020, selling an estimated $1.67M.
- Rockefeller Capital Management's ten largest holdings make up 24% of its $13.2B portfolio in Q4 2020.
- Rockefeller Capital Management opened 401 new positions and closed 168 in Q4 2020.
- Rockefeller Capital Management's portfolio value rose 24% quarter-over-quarter to $13.2B.
Based on Rockefeller Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.